MRK Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 23.96% compared to Merck &'s net margin of 23.56%. Merck &'s return on equity of 40.25% beat Gilead Sciences's return on equity of 2.5%.

Merck & has a consensus price target of $110.89, signalling upside risk potential of 35.37%. On the other hand Gilead Sciences has an analysts' consensus of $111.67 which suggests that it could grow by 6.1%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Merck & has a beta of 0.401, which suggesting that the stock is 59.879% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.86%. Gilead Sciences offers a yield of 2.95% to investors and pays a quarterly dividend of $0.79 per share. Merck & pays 45.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Merck & quarterly revenues are $15.6B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Merck &'s net income of $3.7B is higher than Gilead Sciences's net income of $1.8B. Notably, Merck &'s price-to-earnings ratio is 12.17x while Gilead Sciences's PE ratio is 284.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.24x versus 4.60x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 23.96% compared to Merck &'s net margin of 15.24%. Merck &'s return on equity of 40.25% beat Johnson & Johnson's return on equity of 19.98%.

Merck & has a consensus price target of $110.89, signalling upside risk potential of 35.37%. On the other hand Johnson & Johnson has an analysts' consensus of $171.16 which suggests that it could grow by 13.37%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Merck & has a beta of 0.401, which suggesting that the stock is 59.879% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.86%. Johnson & Johnson offers a yield of 3.29% to investors and pays a quarterly dividend of $1.24 per share. Merck & pays 45.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.6B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Merck &'s net income of $3.7B is higher than Johnson & Johnson's net income of $3.4B. Notably, Merck &'s price-to-earnings ratio is 12.17x while Johnson & Johnson's PE ratio is 26.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.24x versus 4.13x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 23.96% compared to Merck &'s net margin of -117.16%. Merck &'s return on equity of 40.25% beat Moderna's return on equity of -29.09%.

Merck & has a consensus price target of $110.89, signalling upside risk potential of 35.37%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 95.16%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Merck & has a beta of 0.401, which suggesting that the stock is 59.879% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.86%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 45.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.6B, which are larger than Moderna quarterly revenues of $956M. Merck &'s net income of $3.7B is higher than Moderna's net income of -$1.1B. Notably, Merck &'s price-to-earnings ratio is 12.17x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.24x versus 3.23x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 23.96% compared to Merck &'s net margin of 24.22%. Merck &'s return on equity of 40.25% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Merck & has a consensus price target of $110.89, signalling upside risk potential of 35.37%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $904.00 which suggests that it could grow by 56.75%. Given that Regeneron Pharmaceuticals has higher upside potential than Merck &, analysts believe Regeneron Pharmaceuticals is more attractive than Merck &.

Merck & has a beta of 0.401, which suggesting that the stock is 59.879% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.86%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Merck & pays 45.8% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $15.6B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Merck &'s net income of $3.7B is higher than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Merck &'s price-to-earnings ratio is 12.17x while Regeneron Pharmaceuticals's PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.24x versus 4.67x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.